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rNTRODUCTION
Dr. Bruce R. Blazar was this year’s honored E.
onnall Thomas lecturer at the Tandem BMT Meet-
ngs, held on February 12, 2005, in Keystone, Colorado.
r. Blazar is a Professor in the Department of Pediatrics
nd Chief of the Pediatric Blood and Marrow Trans-
lantation Program at the University of Minnesota. He
as been at the forefront of the identiﬁcation of immune
echanisms underlying graft-versus-host disease
GVHD) and marrow rejection. Using these observa-
ions, Dr. Blazar has developed several strategies to block
lloresponses and to facilitate immune recovery after
ransplantation. Some of the most promising strategies
re now being translated clinically. The following text is
modiﬁed transcribed version of the presentation made
y Dr. Blazar.
ECTURE
In this lecture, I would like to share with you some of
ur studies over the past 10 years or more in the area of
egulating alloresponses. First, I will illustrate the role of
ositive and negative T-cell costimulatory pathways in
raft-versus-host disease (GVHD). I will describe imag-
ng studies to visualize GVHD and the impact of co-
timulatory pathway blockade. I will then brieﬂy discuss
VHD effects of CD4/CD25 regulatory T cells,
nd will conclude by describing studies on the use of
maging to visualize the fate of host antidonor responses
esulting in engraftment and graft rejection.
There is a multistage process of GVHD patho-
hysiology, beginning with chemoradiotherapy induc-
ion of tissue injury. Dendritic cells and B cells are
xposed to proinﬂammatory cytokines in uptake tissue
ntigens released by this injury. Antigen-presenting
ells are then stimulated. These cells encounter T cells o
B&MThat become activated, which then clonally expand and
igrate into tissues, where they cause tissue injury, and
his process continues to be ampliﬁed. I will focus on this
xpansion and migration process of GVHD pathophys-
ology in the latter part of this lecture.
In keeping with the requisites for an immune re-
ponse versus tolerance, GVHD as well as other pro-
uctive immune responses involve engagement of ma-
or histocompatibility complex (MHC)/antigen with
-cell receptors (TCRs) along with a second set of
ignals that have been called costimulatory receptors.
hese receptors bind to ligands presented on antigen-
resenting cells so that when donor T cells encounter
ost antigen-presenting cells, both the ﬁrst signal by
his engagement and a second signal by this engage-
ent lead to a fully productive immune response. In
he absence of or inability to receive costimulatory
igands, only a single signal is delivered by the engage-
ent of MHC with TCR and results in either toler-
nce or apoptosis that may be able to modify adverse
lloresponses in vivo. In the presence of signal 2
the costimulatory receptor–ligand interaction) alone,
here is no response. However, not only has the im-
une system evolved to provide positive costimula-
ory signals, but also there are negative regulators that
rovide the immune system with checks and balances.
uch signals are provided by homologous determi-
ants to positive costimulatory receptors and induce a
oinhibitory receptor signal that down-modulates the
mmune response.
The CD28/cytotoxic T lymphocyte antigen-4
CTLA-4)/B7 family, the ﬁrst described costimulatory
athway, delivers both positive signals through CD28
nd negative signals through CTLA-4. T cells that
ngage MHC antigens in the absence of costimulatory
eceptors undergo apoptosis or anergy, which is a state
f alloantigen nonresponsiveness. In the presence of
651
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6he binding of CD28/B7 ligands, T cells proliferate,
ifferentiate, and can acquire effector cell function. In
he presence of CTLA-4, which binds to the same B7
igands as CD28, there is cell cycle arrest and an
bortive immune response. CD28 is expressed on rest-
ng and activated murine T cells, whereas CTLA-4 is
homolog to CD28 and is expressed primarily on
ctivated T cells. B7 ligands bind to both the positive
nd negative receptor, are expressed on antigen-pre-
enting cells, and are up-regulated by proinﬂamma-
ory cytokines that can occur during conditioning,
egimen injury, or GVHD responses.
To illustrate the effect of costimulatory pathway
nvolvement in GVHD, more than 10 years ago ex-
eriments were performed using strains of mice that
ere fully mismatched at the MHC loci with the
onor. Recipients were given lethal total body irradi-
tion and bone marrow rescue, and then spleen cells
ere added as a source of GVHD-causing T cells.
hese and the subsequent murine studies that I will
iscuss in this lecture were led by my colleague, Dr.
atricia Taylor, at the University of Minnesota. Initial
tudies to block costimulation were performed using
TLA4-Ig fusion protein, consisting of the extracel-
ular domain of the CTLA-4 receptor that binds with
igh afﬁnity to B7 ligands, and were linked to an
mmunoglobulin (Ig) fusion partner to prolong sys-
emic protein half-life in vivo. CTLA4-Ig binds to B7
igands and therefore competes with the cell surface
CR, CD28, and CTLA4 for binding to these B7 li-
ands, thereby blocking CD28/CTLA4/B7 responses.
A series of experiments demonstrated that CTLA4-
g, whether of mouse or human origin, clearly was not
ble to protect against GVHD in most cases, although
ccasionally a high level of protection was observed.
ecause CTLA4-Ig binds to B7 ligands and can
ompete with both the binding of CD28 (a positive
ostimulatory pathway) and CTLA4 (a negative co-
timulatory pathway), we investigated whether selec-
ive blockade of the positive costimulatory pathway
ould have a much better outcome in terms of pre-
ention of GVHD lethality. Analogous experiments
ere performed with the GVHD source either wild-
ype donor spleen cells or spleen cells obtained from a
ouse that had the CD28 gene deleted by homolo-
ous recombination.
Both wild-type cells and CD28 knockout T cells
ould cause GVHD lethality. A caveat to these exper-
ments was that these CD28 knockout T cells were
lso deﬁcient in regulatory or suppressor cells (to be
iscussed later). I should point out that we and others
ave shown that CD28 knockout T cells can cause
ery little GVHD if lower cell numbers are infused or
n different strain combinations. Nonetheless, the
omplete absence of a positive costimulatory pathway
ie, CD28), which is critical for the initiation of T-cell
lloresponses, will not prevent lethal GVHD under all
onditions. I
52With respect to the CTLA4/B7 pathway,
TLA4-Ig had only some protective effect, which
ould have been greater had we been able to selec-
ively target CD28 in the absence of blocking
TLA4/B7 interaction. Therefore, experiments were
erformed to determine whether blocking the
TLA4/B7 pathway by infusion of anti-CTLA4 an-
ibody would block the inhibitory signal of T-cell
lloresponses and potentially accelerate GVHD le-
hality. Although recipients of irrelevant antibody died
f GVHD, recipients of anti-CTLA4 antibody had
arkedly accelerated GVHD lethality, demonstrating
hat CTLA4/B7 interactions serve to inhibit GVHD
ethality.
In summary, blockade of the costimulatory
D28/B7 pathway inhibits, but does not eliminate
VHD. Blockade of the coinhibitory CTLA4/B7
athway accelerates GVHD. The incomplete efﬁcacy
f blocking the CD28/B7 pathway suggested that
ther pathways may be contributing to the generation
f a productive immune response culminating in
VHD lethality.
A second member of the CD28 superfamily path-
ay is the inducible costimulator (ICOS). ICOS is
xpressed on activated T cells, and our data indicate
hat it is also expressed on CD4 and CD8 T cells
uring the GVH reaction. The ligand for ICOS is
xpressed on antigen-presenting cells including den-
ritic cells, B cells, and macrophages. Like many of
he ligands in these receptor families, they can be
nduced by proinﬂammatory cytokines in nonlym-
hoid tissue. Signaling via ICOS regulates interleukin
IL)-10, IL-4, and interferon gamma, which are effec-
or-cell cytokines involved in expansion of activated T
ells. In contrast, IL-2, which is critical to the initia-
ion of a T-cell response, is not affected by ICOS
igation. CD28/B7 interactions can occur when rest-
ng T cells encounter host alloantigens, resulting in
nitiation of an immune response including clonal
xpansion and IL-2 production. CD28/B7 binding
ubsequently results in the up-regulation of ICOS on
ctivated T cells. These cells are primed and undergo
ifferentiation to effector cells along with expansion.
To determine the role of ICOS in GVHD lethal-
ty generation, studies were performed using donor
one marrow and either wild-type splenocytes or
COS knockout donor splenocytes. After the infusion
f 5 106 ICOS knockout splenocytes, recipients had
superior survival compared with wild-type control
ecipients. After the infusion of 25  106 ICOS
nockout splenocytes, mice died of GVHD lethality,
emonstrating that the very potent immune response
s not fully dependent on this particular costimulatory
athway, although the recipients survived signiﬁcantly
onger than the recipients of wild-type splenocytes.
irtually identical data have been seen with an anti–
COS-blocking antibody, indicating that the data with
COS knockout splenocytes are due to an aberrant
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Manipulating and Visualizing T-Cell Alloresponses
Bunction induced by using knockout cells. These ﬁnd-
ngs have been found in multiple strain combinations
y several laboratories.
A summary of the CD28/B7 superfamily indicates
hat the GVHD effects of donor T cells are the net
esult of positive costimulatory pathways, such as
D28/B7 and ICOS, and negative pathways, such as
TLA4/B7 or the program death 1 (PD-1) pathway
not covered in this lecture). The CD28 and ICOS
athways are not redundant, because ICOS blockade
educes GVHD when CD28 knockout T cells are
nfused. ICOS blockade is more effective than anti-B7
ntibodies in treating GVHD, likely due to the fact
hat ICOS targets previously activated T cells. The
egree and timing in cell and tissue expression of
ultiple receptor ligand pathways will likely dictate
he biological effects on donor T cells capable of
ausing GVHD. In addition to the multiple pathways
nd multiple tissues, consideration must be given to
he kinetics and level of expression in GVHD target
issues.
The TNF:TNF receptor (R) costimulatory path-
ay members are trimeric proteins expressed on the
ntigen-presenting cells with their counter-receptors
n T cells. This lecture will review data on the CD40:
D40 ligand (L) pathway in detail and then summa-
ize data on the remaining pathway members, the
-1BB, OX40, and CD30 pathways. CD40L is ex-
ressed predominantly on activated CD4 T cells.
he counter-receptor, CD40, is expressed on antigen-
resenting cells and on activated endothelial and epi-
helial cells. The binding of CD40L to CD40 regu-
ates immunoglobulin isotype switching, indicative of
cell:B cell cooperation.
Studies were performed using an irrelevant or
nti-CD40L antibody to determine whether block-
de of this pathway could inhibit GVHD lethality.
similar story has evolved in which members of the
NF/TNFR superfamily can block GVHD under
onditions of a more limited donor T-cell number.
fter infusion of 15  106 splenocytes, 50% of
nti-CD40L antibody-treated MHC-disparate re-
ipients survived versus 100% lethality in the con-
rol group. However, as with other costimulatory
athways, blockade of this pathway can be over-
helmed under very aggressive immune responses,
s seen after the infusion of 25  106 splenocytes.
lthough biological effects were observed in terms
f delaying GVHD mortality time, recipients ulti-
ately uniformly succumbed to GVHD lethality.
The results with the TNF/TNFR pathways can be
ummarized as follows:
. Because CD4 T cells exhibit CD40L expression dur-
ing a GVHD response, GVHD systems that are medi-
ated only by CD4 T cells can be inhibited by CD4L:
CD40 blockade. CD8 T-cell–mediated GVHD
systems are not effected, although GVHD systems in C
B&MTwhich both CD4 and CD8 T cells are required to
cause optimal GVHD lethality can be inhibited.
. Results for the CD30 pathway are similar, demonstrat-
ing the effects of CD30:CD30L blockade on CD4 or
combined CD4 and CD8 T-cell–mediated GVHD.
Despite the expression of CD30 on CD8 T cells an-
alyzed during a GVHD response, little effect was seen in
a CD8 T-cell–mediated GVHD system.
. For the 4-1BB pathway, although 4-1BB is expressed
on alloreactive CD4 and CD8 cells, there is a more
dominant effect on inhibiting CD4 responses. There are
some effects on CD8 T-cell–mediated GVHD and an
effect on GVHD mediated by both CD4 and CD8
T cells.
. Relevant to the OX40 pathway, alloreactive cells express
OX40 on both CD4 and CD8 T cells, and OX40:
OX40L blockade inhibits GVHD in systems in which
GVHD is mediated by CD4 T cells, CD8 T cells,
and both CD4 and CD8 T cells.
With respect to the latter two pathways, of note,
-1BB has been reported as a survival factor for
D8 T cells responding to nominal antigens, al-
hough for GVHD lethality induction, we have noted
more dominant effect on CD4 T-cell–mediated
VHD. In contrast, whereas OX40 has been reported
o be a survival factor predominantly for CD4T-cell
esponses to nominal antigens, blockade of CD8
-cell–mediated GVHD provides signiﬁcant biologi-
al effects on outcome. Thus, overall, CD4 T-cell–
ediated GVHD can be inhibited by any of these
NF:TNFR family pathway blockades studied to
ate. CD8 T-cell–mediated GVHD is most depen-
ent on OX40 and to a lesser extent on 4-1BB signals,
ontrary to what would have been surmised from the
iterature, at least under these conditions. In addition,
he CD28 and TNFR family members are nonredun-
ant, as shown in studies using CD28 knockout T
ells.
The limitations to performing in vivo antibody
lockade or using knockout T cells for experiments
nclude the presence of proinﬂammatory cytokine re-
ponses and tissue destructive events that occur in vivo
n GVHD model systems. Thus, sufﬁcient inhibition
f T-cell priming or expansion by blockade of a single
athway in vivo may be difﬁcult. A successful ex vivo
pproach could be advantageous by permitting the
nfusion of donor T cells that are incapable of causing
lloresponses, so that when they encounter this in-
ammatory environment in vivo, they have already
een incapacitated, and these multiple pathways then
annot be fully operative in promoting a GVHD re-
ponse. Blockade of the CD40L or CD28/B7 path-
ays may be especially useful in CD4 T-cell tolerance,
ecause of their critical role in initiating alloantigen
esponses.
Consequently, Dr. Taylor developed ex vivo tol-
rance approaches based on cultures containing
D4 T cells and irradiated MHC class II-disparate
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6rradiated host antigen-presenting cells. These cul-
ures were performed in the presence or absence of
nti-CD40L. T cells were analyzed in vitro for im-
une responses, and an aliquot was infused in vivo
nto MHC class II-disparate recipients to determine
hether these tolerized cells could cause GVHD le-
hality. Control cells responded vigorously in vitro to
lloantigen expressed on host antigen-presenting cells.
n the presence of anti-CD40L antibody, this re-
ponse was markedly blunted. There was no effect of
nti-CD40L antibody on day 2, because it takes 24 to
8 hours to up-regulate CD40L. In the presence of
L-2, the immune response was intact. In secondary
ultures using CD4 T cells washed free of antibody,
xposure to alloantigen rechallenge in the complete
bsence of antibody resulted in a marked alloantigen
yporesponsiveness. After the infusion of 1  106
ells, all recipients survived, whereas the infusion of 3
104 control cultured cells caused 94% lethality. The
pproximate reduction in the GVHD lethality capac-
ty of tolerized cells was estimated to be approximately
0-fold. In comparison, the administration of anti-
D40L antibody in vivo resulted in an approximate
-fold inhibition of GVHD, which was at least 10-fold
ess than that achieved with ex vivo tolerized cells.
Based on these data, we investigated the possible
uppressor-cell activity of these tolerized T cells,
hich could explain the markedly superior GVHD
rotective effect of tolerized cells compared with in
ivo anti-CD40L antibody infusion. Additional sup-
orting data for this hypothesis were derived from
tudies in which we demonstrated that CD4 T cells
eﬁcient in CD40L had an approximate 3-fold reduc-
ion in GVHD lethality capacity. Tolerized T cells
ave the appearance of T cell activation by ﬂow cy-
ometry, as compared to naive CD4 T cells, based
n forward- and side-scatter properties. Biochemical
nalyses of these tolerized cells showed that some
ntracellular pathways were increased, indicating that
olerized cells had been activated. Collectively, these
ata suggested the possibility that the tolerized cells
ad acquired suppressor-cell features.
To determine whether tolerized cells had suppres-
or-cell properties, CD4 T cells were tolerized and
hen analyzed in vitro to determine whether they
ould inhibit a naive CD4 T-cell response to al-
oantigen in MLR culture. In addition, an aliquot of
ells was injected in vivo to determine whether toler-
zed cells could down-regulate a GVHD lethality re-
ponse mediated by fresh naïve CD4 T cells.
hereas naive CD4 T cells alone had a vigorous
roliferative response to alloantigenic stimulators, the
mmune response in the presence of as few as 1:3
olerized:naïve cells was markedly blunted. With as
ew as 1:100 tolerized:naïve cells, the immune re-
ponse was reduced by 50%, indicating potent in vitro
uppressor-cell activity. Whereas the in vivo infusion
f 1  105 fresh CD4 T cells was uniformly lethal a
54hen given to sublethally irradiated MHC class II-
isparate recipients (the same strain as the stimulator
ells used for tolerization), the separate injection of as
ew as 3  104 tolerized cells that are widely distrib-
ted throughout the animal results in 70% long-term
urvival, indicating very potent suppressor-cell activity
n vivo.
These data led us to examine the role of CD4/25
egulatory/suppressor cells. Tolerized CD4 T cells ex-
ressed high levels of CD25 antigen during our culture.
epletion of these CD4/25 cells completely pre-
luded tolerance induction by either CD40L/CD40
athway blockade or CD28/CTLA4/B7 pathway block-
de. Thus CD40L antibodies favor the outgrowth of
D4/25 T cells with suppressor-cell activity, as we
reviously demonstrated in other experiments. The high
egree of suppression of GVHD lethality by these toler-
zed cells suggested that activated CD4/25 cells
lone were responsible. This led us to experiments to
solate CD4/25 cells and expand them in culture
or a period of 1 to 2 weeks by providing TCR signals
hrough CD3 engagement, which increases their po-
ency, as well as survival factors, including IL-2 and
ither TGF- or CD28 costimulatory signals. These
ells can expand up to 40- to 67-fold under these
onditions and have increased potency compared with
aïve T cells, as seen in studies performed by Dr.
aylor and many others. To determine the extent of
uppression of GVHD lethality that could be
chieved, donor bone marrow and supplemental
plenocytes were given to a fully MHC-disparate
train combination, as described earlier, along with
he infusion of 1  107 ex vivo expanded CD4/25
cells on days 0 and 4. In contrast to the uniform
ethality of the control groups, the infusion of CD4/
5 T cells resulted in 80% to 100% survival, a result
lso observed in other laboratories for other strain
ombinations.
These murine data prompted us to determine
hether human CD4/25 T cells could be isolated
nd expanded as a possible strategy to inhibit GVHD
ethality in the clinic. In contrast to the mouse, human
D4/25 T cells are not as readily identiﬁable as a
iscrete population in human peripheral blood.
ather, there is a continuum of CD25 antigen expres-
ion. Only cells with the highest density of CD25
xpression have suppressor-cell function, and these
ells are present in low frequency (typically 1% to 2%
f peripheral blood CD4 T cells). In studies initi-
ted by Dr. Wayne Godfrey while at the University of
innesota, a bead isolation procedure was developed
o acquire the highest CD25 antigen-expressing
D4 T cells from both adult peripheral blood and
ord blood cells. In the presence of CD3/CD28 beads,
imilar to the procedure used in mice, we have noted
hat these cells can expand at least 100-fold in three
eeks, potently suppressing an allo-MLR response. In
bout 2/3 of instances, isolated peripheral blood
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Manipulating and Visualizing T-Cell Alloresponses
BD4/25 T cells suppressed the immune response
y  50% at ratios of 1:2 CD4/25:CD4/
D25 responder T cells. In the coming year,
D4/25 T cells will be studied by multiple labo-
atories both in the United States and abroad for their
otency in GVHD prevention in humans.
We sought to extend these data to determine how
VHD-suppressive approaches, such as costimula-
ory pathway blockade and CD4/25 T-cell infu-
ion, inﬂuence GVHD T-cell effector-cell expansion
nd their homing and migration to GVHD target
rgans. A better understanding of the precise biology
f these processes should allow improvement in
VHD prevention. To accomplish these studies, we
sed T cells from a donor mouse that expressed green
uorescent protein (GFP) using a system initially de-
cribed by our collaborator, Dr. Angela Panoskaltsis-
ortari at the University of Minnesota. The use of
FP transgenic cells permit tracking of GVHD effec-
or-cell trafﬁcking, including analysis of GVHD tar-
et organs and the kinetics of their inﬁltration into
hese organs using animal imaging techniques begin-
ing on day 1 after transplantation. At 1 week and 2
eeks after infusion, inguinal lymph nodes, spleen,
nd intestinal Peyer’s patches each exhibited marked
nﬁltration of these cells consistent with the GVHD
ffector-cell response. There was a diffuse inﬁltration
hroughout the small and large intestines, the liver,
nd the lung, which is also a target of GVHD.
This model was used to determine the effects of
ostimulatory pathway blockade. For the purpose of
llustration, I will focus on ICOS pathway blockade in
tudies led by Dr. Taylor, who analyzed the effects of
reating recipients of GFP transgenic T cells with
rrelevant immunoglobulin or anti-ICOS antibody,
ollowed by sequential whole-animal imaging of co-
orts of mice at different times after transplantation.
n the control group, intestinal loops had a marked
nﬁltration with GFP transgenic T cells at 1 week
osttransplantation that increased by 2 weeks post-
ransplantation. Anti-ICOS antibody markedly inhib-
ted the inﬁltration in the intestine at both the 1-week
nd 2-week time points, although some cells clearly
scaped at both time points, as was observed in the
eyer’s patches. Anti-ICOS antibody delayed the in-
ltration into lymph nodes, although some cells es-
aped through this process. These probably were the
ells capable of expanding in sufﬁcient numbers under
igh doses (25  106) that were responsible for the
VHD lethality using ICOS knockout splenocytes
iscussed earlier.
Similarly, in the liver, inﬁltration was inhibited
ery early after transplantation, and there were some
scapees that appeared later after transplantation.
hus ICOS blockade reduced or delayed GFP T-cell
nﬁltration into lymphoid and other GVHD target
rgans. Similar but more profound results were seen
ith CD4/25 T-cell infusions. Therefore, for us l
B&MTnd others using luciferase-based techniques, whole-
nimal imaging has proven to be a powerful tool for
isualizing GVHD, providing insight into how inter-
entions may affect the expansion, homing, and mi-
ration properties of donor effector T cells.
GVHD and host-versus-graft (HVG) responses
re opposing immunological effects. Dominant GVH
esponses will result in GVHD, whereas dominant
VG responses will result in bone marrow rejection.
onor anti-host T cells can cause GVHD, whereas
ost anti-donor T cells and host natural killer (NK)
ells can cause bone marrow graft rejection. The
echanism, sites, and kinetics of bone marrow graft
ejection is not well understood, and such knowledge
ay enable the development of strategies to facilitate
lloengraftment after transplantation.
To better understand the fate of these donor T
ells under various conditions of engraftment and
raft resistance, Dr. Taylor applied the GFP imaging
ystem to study the fate of GFP transgeneic T-cell–
epleted bone marrow cells infused into sublethally
rradiated fully allogeneic recipients. Dynamic imag-
ng of the animals revealed showed bone marrow cells
n the bone marrow cavity, inguinal lymph nodes,
eyer’s patches, and spleen and disseminating widely
nto lymphohematopoietic organs. At 1 week after
ransfer, GFP transgenic cells were seen in the liver,
ung, intestinal loops, and colon, the same sites to
hich GVHD effector cells migrate and known sites
f alloresponses. In an attempt to better understand
he immunobiology responsible for allogeneic graft
ejection, recipients were irradiated, and then host-
ype allogeneic T cells were infused. Under these
onditions, in the absence of host T cells, recipients all
urvived and had a mean 74% donor cell engraftment.
n the presence of adoptively transferred host T cells,
hese recipients now rejected their grafts and died of
one marrow aplasia, as determined by evaluation of
ematocrit and other analyses.
Subsequent studies used GFP transgeneic host-
ype T cells to permit whole-body imaging. The co-
nfusion of syngeneic bone marrow stimulated very
ittle migration of host-type T cells into the bone
arrow cavity, in contrast with allogeneic bone mar-
ow, which resulted in host-type T-cell inﬁltration
nto the bone marrow cavity on day 4. By 1 week
osttransplantation, a large number of these host-type
cells inﬁltrated into the bone marrow cavity, sug-
esting the possibility that these host-type T cells may
e rejecting bone marrow in situ. However, these
ost-type T cells do not only go to bone marrow; they
lso migrate to other sites where the bone marrow also
omes, including the lymphoid system. For example,
arge numbers of host-type T cells were seen in the
nguinal lymph nodes on day 7 posttransplantation in
ecipients receiving allogeneic bone marrow, whereas
ar fewer host-type T cells were seen in the inguinal
ymph nodes in recipients receiving syngeneic bone
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6arrow. These data demonstrate that an expansion
nd migration of host-type T cells occurs in lymph
odes on exposure to allogeneic bone marrow. Find-
ngs for Peyer’s patches and the spleen were similar,
ith a more intense inﬁltration of host-type T cells in
ecipients of allogeneic bone marrow than in recipi-
nts of syngeneic bone marrow, providing a vivid
llustration of HVG T-cell responses.
Recipient allosensitization can be a signiﬁcant bar-
ier to bone marrow engraftment under some condi-
ions. Multiple-transfused aplastic anemia patients are
t higher risk for graft rejection due to priming of host
ntidonor immune responses. Alloprimed mice also
an reject donor bone marrow grafts. In an effort to
etter understand the mechanisms that may be re-
ponsible (at least under these rodent conditions) for
onor bone marrow graft rejection under allosensiti-
ation conditions, recipients were sublethally irradi-
ted and infused with GFP transgenic donor bone
arrow. Cohorts of recipients were sensitized at 1
onth before transplantation to provide an alloprim-
ng situation. (Nonsensitized recipients given 350 cGy
f irradiation would reject donor bone marrow grafts
nless pan-T-cell–depleting antibodies were given.)
n day 3 posttransplantation, few bone marrow cells
ere present in rejecting recipients. These GFP trans-
enic bone marrow cells expanded by day 6, but were
ost by day 14 posttransplantation. In the engrafting
nimals that were not allosensitized but had received
an-T-cell–depleting antibodies, comparable data
ere observed in the ﬁrst 6 days posttransplantation.
n contrast, GFP transgenic bone marrow was present
n higher numbers in engrafted mice on day 14 than
n day 6 posttransplantation. In allosensitized mice
here was a complete absence of GFP transgenic do-
or bone marrow in bone marrow cavities at all time
oints posttransplantation. At 18 hours posttransplan-
ation (the earliest time point examined), there was a
omplete absence of donor bone marrow in al-
oprimed recipients. GFP transgenic donor bone mar-
ow also migrated to secondary lymphoid organs and
VHD target organs. Findings in these organs mir-
ored those in the bone marrow cavity, such that GFP
ransgenic donor bone marrow cells were present in
ach site in engrafting mice on day 3 and in higher
umbers on day 6 posttransplantation, but were lost
y day 14 posttransplantation in rejecting but not
ngrafting mice. In contrast, no GFP transgenic do-
or bone marrow was seen in any site by 18 hours after
ransfer in rejecting mice.
To determine whether host T cells or NK cells
ere responsible for this primed bone marrow graft
ejection, mice that had received no manipulation or
ad been primed with donor splenocytes 1 month
efore transplantation were given lethal irradiation
nd full allogeneic donor bone marrow rescue. Primed
ice were also given irrelevant antibody or antibodyhat depleted CD4 and CD8 T cells and NK cells. p
56hereas nonprimed mice survived and had high lev-
ls of donor cell engraftment, primed mice given ir-
elevant antibody succumbed due to bone marrow
plasia. Despite T-cell and NK-cell depletion, recip-
ents could not be rescued from bone marrow aplasia;
n fact, there was no inﬂuence of pan-T-cell and NK-
ell depletion on the time to mortality under these
eavy irradiation conditions.
Because combined T-cell and NK-cell depletion
ad no observable effects in primed mice, we explored
he possibility that host antidonor alloantibody was
esponsible for eliminating donor bone marrow cells
nd inducing bone marrow aplasia. Experiments were
erformed using nonsensitized or sensitized recipients
hat were irradiated and rescued with very high doses
f donor bone marrow in an attempt to overcome
raft rejection. Recipients were wild-type or B-cell–
eﬁcient animals due to the absence (by homologous
ecombination) of the  heavy chain of immunoglob-
lin. Under the wild-type conditions, the unprimed
ice engraft and survive, while the primed mice uni-
ormly die. In the complete absence of B cells, recip-
ent survival is high with complete donor chimerism
espite priming. Of note, however, in experiments
sing a 10-fold–lower donor bone marrow cell dose
nfused into allosensitized B-cell–deﬁcient mice, re-
ection will occur, indicating that -knockout mice are
apable of mounting a non–antibody-mediated re-
ponse after allosensitization. Furthermore, incuba-
ion of donor-type thymocytes with sera obtained
rom sensitized mice demonstrated binding even at
igh serum dilutions, whereas such binding was not
bserved using third-party thymocytes at these low
erum concentrations.
In summary, donor bone marrow rejection is far
ore rapid in alloprimed mice than in unprimed mice,
ccurring in 1 day in the former versus 1 week in
he latter. Alloantibody production can be detected,
nd imaging provides a vivid illustration of homing/
igration patterns of donor bone marrow and host
ntidonor T cells, which should be useful in develop-
ng strategies to facilitate alloengraftment.
We have many opportunities to control the im-
une response in bone marrow transplantation by
argeting the costimulatory pathway receptor/ligand-
inding interactions that regulate productive immune
esponses, as well as taking into account the coinhibi-
ory pathways and CD4/25 T cells that are at-
empting to down-regulate GVHD responses. Al-
hough the immune system incorporates a series of
hecks and balances to permit life-saving immunity
nd to protect against uncontrolled or unwanted T-
ell activation, immune manipulation via costimula-
ory and coinhibitory pathways or cellular therapy
ased on these principles will undoubtedly improve
he outcome of allogeneic transplantation of human
atients in the coming years.
